TMFBiologyFool

Brian Orelli

Somewhere between his graduate thesis on BRCA1, a gene that causes hereditary breast cancer, and his postdoctoral fellowship in DNA repair, Brian realized he enjoyed analyzing other people's data more than running his own experiments. Having gotten his first taste of how to analyze stocks from The Motley Fool many years prior, it was only fitting that he came full circle and started writing about biotech, pharmaceutical, and medical device companies for Fool.com. He also covers the health insurance industry to keep from going into binary-event overload. When not writing at The Motley Fool or trade journals like Nature Biotechnology and BioWorld, Brian can be found coaching soccer or hanging out at the beach in his hometown of San Diego.

TMFBiologyFool’s Activity

Yesterday

NL

Article

TMFBiologyFool published an article 7:59 PM

Biogen Idec Inc Earnings: Worth the Wait

Snow storms can't slow Biogen Idec's sales growth.

Rule Breakers article.

TMFBiologyFool published an update. 5:14 PM

NL

Article

TMFBiologyFool published an article 2:46 PM

Celgene Corp.'s Expanding Margins

But it wasn't all the healthy kind of expansion.

Rule Breakers article.

TMFBiologyFool published an update. 10:00 AM

Wed Jan 28

NL

Article

TMFBiologyFool published an article 7:48 PM

No Surprises From Vertex Pharmaceuticals Incorporated. Yet.

Having pre-released revenue and guidance at J.P. Morgan, Vertex didn't offer much news on its earnings call, although we should get news soon.

Hidden Gems article.

TMFBiologyFool published an update. 3:43 PM

NL

Article

TMFBiologyFool published an article 2:01 PM

Natus Medical Inc. Serves Up a New Business Model

The medical device maker moves further into testing services.

Fri Jan 23

Rule Breakers article.

TMFBiologyFool published an update. 10:00 AM

Thu Jan 22

NL

Article

TMFBiologyFool published an article 7:14 PM

Don't Fret About Intuitive Surgical, Inc.'s Lower Gross Margins

Earnings fall despite an increase in revenue, but investors shouldn't panic.

Wed Jan 21

Rule Breakers article.

TMFBiologyFool published an update. 4:47 PM

NL

Article

TMFBiologyFool published an article 4:14 PM

Intuitive Surgical Inc. Slices Revenue and Earnings Releases

Intuitive Surgical released four-quarter revenue last week, but we'll get the earnings number on Thursday.

NL

Article

TMFBiologyFool published an article 1:29 PM

State of the Union Address Investing Idea: Precision Medicine

There are plenty of companies developing precision medicine drugs already, and investors would be wise to watch key players.

Sun Jan 18

NL

Article

TMFBiologyFool published an article 2:03 AM

MannKind Corporation on Track for Afrezza Launch

MannKind partner Sanofi is close to launching its inhaled insulin Afrezza, but will doctors prescribe it?

Thu Jan 15

NL

Article

TMFBiologyFool published an article 2:31 PM

Vertex Pharmaceuticals Going to Get Fat on Cystic Fibrosis Pie

Different drugs for different cystic fibrosis patients.

Wed Jan 14

NL

Article

TMFBiologyFool published an article 12:52 PM

Gilead Sciences, Inc. Is No Longer Just an HIV Company

HIV drugs now make up less than half of Gilead Sciences' revenue.

Tue Jan 13

NL

Article

TMFBiologyFool published an article 3:56 PM

Celgene Corporation's Future: Everything You Need to Know in 5 Slides

Celgene presents at the JP Morgan Healthcare Conference.

NL

Article

TMFBiologyFool published an article 11:13 AM

Less Mann in MannKind Corporation

Alfred Mann retires as CEO, but investors needn't worry.

Fri Jan 9

NL

Article

TMFBiologyFool published an article 3:37 PM

Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest

The week before JPMorgan Healthcare conference brought a plethora of deals and data.

NL

Article

TMFBiologyFool published an article 3:37 PM

Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest

The week before JPMorgan Healthcare conference brought a plethora of deals and data.

Thu Jan 8

NL

Article

TMFBiologyFool published an article 3:02 PM

Arena Pharmaceuticals Inc.'s Phase 1 Data is Worth $550 Million!?

Investors bid up Arena Pharmaceuticals 76% after the biotech releases positive phase 1 data for APD334.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 98.06
Player Rank 1456 out of 75117
Score 2013.06
Score Change Today -57.53
Accuracy 66.83%
Active Picks 72
Total Picks 213
Best Pick ISIS (+432.64)
Worst Pick INCY (-743.73)
Average Score per Pick 9.45
Charms Earned 11
Highest Rated Favorite zzlangerhans
Go to TMFBiologyFool’s CAPS page

Boards Stats & Trivia

Three stars, 500 posts CAPS All Star
Board Posts 928
Recs Received 982
People who have rec'd these posts 380
Recs to Posts Ratio (last 30 days) N/A
Threads Started 90
Threads Started Percentage 9.70 %
Most Frequent Board Buying or Selling a Home
Very First Post Re: How many is enough? (6/6/2001)
Percentage of Posts Rec'd 48.17 %
Show TMFBiologyFool’s 10 Latest Posts